Article
Oncology
Zhichen Sun, Rutian Li, Yun Shen, Siyi Tan, Naiqing Ding, Ruihan Xu, Xinyue Wang, Jia Wei, Baorui Liu, Fanyan Meng
Summary: This study introduces a novel universal CAR-T cell therapy for solid tumors, utilizing fusogenic nanoparticles for in situ modification of exogenous antigens, which successfully activates CAR-T cells and demonstrates antitumor effects on multiple types of tumor cells.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2022)
Article
Immunology
Wei Sang, Xiangmin Wang, Hongzhi Geng, Tianci Li, Dashan Li, Bingpei Zhang, Yi Zhou, Xuguang Song, Cai Sun, Dongmei Yan, Depeng Li, Zhenyu Li, Caixia Li, Kailin Xu
Summary: The combination of anti-CD30 CAR-T therapy with PD-1 inhibitor showed enhanced efficacy in patients with relapsed/refractory CD30+ lymphoma. The overall response rate was 91.7%, with minimal toxicities. Cohort 3, which received the combination therapy, achieved a 100% overall response rate and an 80% complete remission rate.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Cell Biology
Jing Guo, Shuai He, Yongjie Zhu, Wei Yu, Dong Yang, Xudong Zhao
Summary: This study demonstrates that CD30-directed CARs constructed using humanized antibody fragments show comparable efficacy to those using mouse antibodies in vitro and in a mouse model. Humanized CARs have the advantages of reducing immune rejection and improving cell persistence.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Article
Biotechnology & Applied Microbiology
Stephanie Choi, Melissa A. Pegues, Norris Lam, Claudia Geldres, Danielle Vanasse, James N. Kochenderfer
Summary: The study compared three different anti-CD30 CAR designs and found that 5F11-28Z CAR was most effective at eradicating tumors, while 5F11-CD8BBZ CAR was the least effective. T cells expressing 5F11-CD8BBZ exhibited higher levels of nonspecific functional activity compared to CD28-containing CARs when stimulated with CD30-negative target cells.
HUMAN GENE THERAPY
(2021)
Review
Cell Biology
Marzieh Nikoo, Mohammad Rudiansyah, Dmitry Olegovich Bokov, Nurlan T. Jainakbaev, Wanich Suksatan, Mohammad Javed Ansari, Lakshmi Thangavelu, Supat Chupradit, Amir Zamani, Ali Adili, Navid Shomali, Morteza Akbari
Summary: Despite significant advancements in conventional treatments, breast cancer remains the leading cause of cancer death in women. CAR-T and CAR-NK cell therapies have emerged as promising approaches for treating breast cancer, but their differences require further research and improvement.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
(2022)
Article
Oncology
Zhenling Guo, Sanfang Tu, Siyao Yu, Liufang Wu, Wanying Pan, Ning Chang, Xuan Zhou, Chaoyang Song, Yuhua Li, Yanjie He
Summary: CD19-specific CAR T-cell therapy has shown significant efficacy in treating B-cell hematological malignancies, but targeted antigen-negative relapse poses a challenge to its widespread application. Researchers have explored alternative targets and tested combination antigen CAR T-cell therapies to enhance treatment effectiveness.
Article
Immunology
Carmen Alvarez-Fernandez, Laura Escriba-Garcia, A. C. Caballero, Eva Escudero-Lopez, Cristina Ujaldon-Miro, Rosanna Montserrat-Torres, Paula Pujol-Fernandez, Jorge Sierra, Javier Briones
Summary: A novel CD30-CAR T cell therapy using T-SCM has shown improved efficacy in eradicating Hodgkin lymphoma in preclinical experiments, with the T cells exhibiting high persistence and enhanced antitumor activity compared to traditional CAR T cells.
CLINICAL & TRANSLATIONAL IMMUNOLOGY
(2021)
Article
Oncology
Damian Kovalovsky, Jeong Heon Yoon, Matthew G. Cyr, Samantha Simon, Elisaveta Voynova, Christoph Rader, Adrian Wiestner, Julie Alejo, Stefania Pittaluga, Ronald E. Gress
Summary: A novel CAR-T cell therapy targeting Siglec-6 for chronic lymphocytic leukemia was developed and shown to specifically target CLL cells. Additionally, Siglec-6 was identified as a potential target for immunotherapy based on the findings of this study.
Article
Oncology
Peiwei Yang, Fan Yu, Zheng Yao, Xu Ding, Hanmei Xu, Juan Zhang
Summary: This study verified the potential application of chimeric antigen receptor-T cells (CAR-T cells) targeting CD24 in the treatment of triple negative breast cancer (TNBC). 24BBz showed antigen-specific activation and dose-dependent cytotoxicity against CD24-positive breast cancer cells in vitro. In TNBC xenograft models, 24BBz exhibited significant anti-tumor effect. CD24-specific CAR-T cells have potent anti-tumor activity and potential application value in TNBC treatment.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Article
Oncology
Jordi Pfeifer Serrahima, Congcong Zhang, Pranav Oberoi, Malena Bodden, Jasmin Roeder, Claudia Arndt, Anja Feldmann, Anne Kiefer, Maren Pruefer, Ines Kuehnel, Torsten Tonn, Michael Bachmann, Winfried S. Wels
Summary: Chimeric antigen receptor (CAR)-engineered immune effector cells show promise in cancer immunotherapy, but face challenges of toxicity and immune escape. Adaptor CARs triggered by bispecific molecules that crosslink CAR with tumor-associated antigens may overcome these challenges. In this study, NK cells were genetically modified to express a universal CAR (UniCAR) and redirected to tumor cells using target modules (TMs) containing an ErbB2-specific antibody domain and a UniCAR-recognized peptide. Different TM designs and CAR compositions affected cell killing activity, with TMs carrying two or three E5B9 epitopes being more effective with the first-generation UniCAR, while the second-generation UniCAR was more active with TMs carrying one E5B9 sequence. These findings have implications for the development of optimized UniCAR and TM combinations in cancer immunotherapy.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Article
Immunology
Dan Liu, Jiacong Yan, Jiahui Sun, Bo Liu, Weiwei Ma, Ye Li, Xingxing Shao, Hai Qi
Summary: BCL6 is crucial for the development of follicular T helper (Tfh) cells and germinal center (GC) formation. It affects Tfh calcium signaling and controls their interaction with B cells, as well as the delivery of CD40L. Additionally, changes in T-B cell interactions can impact BCL6 protein levels and Tfh cell frequencies.
Article
Cell & Tissue Engineering
Qingyi Huo, Jiang Lv, Jianzhong Zhang, Haiqiong Huang, Huayong Hu, Yaoxin Zhao, Xinrui Zhang, Yingqi Wang, Yiyi Zhou, Junchao Qiu, Yanmei Ye, Aiqun Huang, Yanhong Chen, Le Qin, Dajiang Qin, Peng Li, Gang Cai
Summary: This study identifies c-Met as a highly expressed target in recurrent nasopharyngeal carcinoma tissues and confirms its potential as a target for CAR-T therapy.
Article
Oncology
Phatchanat Klaihmon, Sudjit Luanpitpong, Xing Kang, Surapol Issaragrisil
Summary: This study successfully engineered a clonal master iPSC carrying a third-generation anti-TIM3 CAR and differentiated it into functional anti-TIM3 CAR-NK cells, demonstrating enhanced anti-tumor activity against TIM3-positive AML cells.
CANCER CELL INTERNATIONAL
(2023)
Article
Oncology
Allyson C. Banville, Maartje C. A. Wouters, Ann L. Oberg, Krista M. Goergen, Matthew J. Maurer, Katy Milne, Jahanshah Ashkani, Emma Field, Chanel Ghesquiere, Steven J. M. Jones, Matthew S. Block, Brad H. Nelson
Summary: In the majority of cases of HGSC, CA125, MSLN, and FOLRA are overexpressed at the transcriptional level, but MSLN and FOLRA also show significant expression in healthy tissues. At the protein level, CA125 has the highest expression proportion, followed by MSLN and FOLRA. The combination of CA125 and/or MSLN is the most promising, with over 90% of tumor cells expressing one or both antigens in 51.9% of cases.
GYNECOLOGIC ONCOLOGY
(2021)
Letter
Oncology
Jingwen Tan, Yujie Jia, Meixia Zhou, Chengcheng Fu, Israth Jahan Tuhin, Jing Ye, Masuma Akter Monty, Nan Xu, Liqing Kang, Minghao Li, Jiaqi Shao, Xiaoyan Fang, Hongjia Zhu, Lingzhi Yan, Changju Qu, Shengli Xue, Zhengming Jin, Suning Chen, Haiwen Huang, Yang Xu, Jia Chen, Miao Miao, Xiaowen Tang, Caixia Li, Zhiqiang Yan, Depei Wu, Lei Yu
Summary: This study demonstrates that OX40-CAR-T cells have better persistence and proliferative capacity than 41BB-CAR-T cells in BCMA-targeting CAR-T cell therapy, providing a scientific basis for improving relapse in patients with multiple myeloma after CAR-T treatment.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2022)
Article
Nanoscience & Nanotechnology
Youngee Seo, Lida Ghazanfari, Alyssa Master, Hemant M. Vishwasrao, Xiaomeng Wan, Marina Sokolsky-Papkov, Alexander Kabanov
Summary: This study reports the development of a novel theranostic system called NanoFerrogels, which combines magnetic nanoparticles and polymeric micelles for cancer diagnosis and treatment. NanoFerrogels function as imaging agents for magnetic resonance imaging and as drug loading compartments. The experiments demonstrate the potential of NanoFerrogels as a remotely actuated theranostic platform for cancer therapy.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
(2022)
Article
Oncology
David J. Hermel, Jason Cham, Samantha R. Spierling Bagsic, Lee K. Hong, Carrie L. Costantini, James R. Mason, Alan Saven, Darren S. Sigal
Summary: This study examined the clinical characteristics of cancer patients hospitalized with COVID-19 and found that cancer patients receiving systemic anti-cancer treatment had significantly increased odds of mortality compared to those not on treatment, especially in patients with lung involvement.
Article
Medicine, Research & Experimental
Tao Zhang, Jinghua Cai, Muyun Xu, Xinrui Ma, Hui Wang, Mengzhe Wang, Zhaoguo Han, Jason Wang, Eric Smith, Zibo Li, Zhanhong Wu
Summary: A new series of F-18-labeled PSMA-targeting agents were developed with optimal tumor uptake and contrast. Among them, F-18-PEG(3)-VS-PSMAi demonstrated nearly double the tumor uptake compared to the FDA-approved Ga-68-PSMA-11 in the same animal model.
MOLECULAR PHARMACEUTICS
(2022)
Article
Chemistry, Multidisciplinary
Wei Chen, Hui Wang, Nicholas E. S. Tay, Vincent A. Pistritto, Kang-Po Li, Tao Zhang, Zhanhong Wu, David A. Nicewicz, Zibo Li
Summary: PET is a powerful imaging technology used to visualize and measure metabolic processes and obtain unique information about drug candidates. The development of new and improved molecular probes in PET is crucial, but progress is restricted by the lack of efficient and simple labeling methods. This study introduces a method for constructing C-F-18 bonds through direct halide/F-18 conversion in electron-rich halo(hetero)arenes, enabling rapid diversification of PET probes.
Article
Immunology
Daniel Michaud, Bhalchandra Mirlekar, Colleen Steward, Gail Bishop, Yuliya Pylayeva-Gupta
Summary: B cells can suppress anti-tumor T cell immunity in pancreatic cancer through the expression of IL-35. The synergy between BCR and TLR4 signaling pathways induces IL-35 expression in B cells. B cell receptor activation, rather than MyD88 signaling, is crucial for B cell-mediated suppression and promotion of pancreatic cancer growth. PKD2 is identified as a key downstream regulator of IL-35 expression in B cells.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Soha Bazyar, Edward Timothy O'Brien, Thad Benefield, Victoria R. Roberts, Rashmi J. Kumar, Gaorav P. Gupta, Otto Zhou, Yueh Z. Lee
Summary: Radiation therapy is commonly used in cancer treatment, but can have negative effects on normal tissues. Microplanar radiation therapy (MRT) is a novel method that has shown promising results in animal models. Combining MRT with immune checkpoint therapy can enhance the treatment efficacy against tumors.
Article
Materials Science, Biomaterials
Matthew J. Haney, Hong Yuan, Steven T. Shipley, Zhanhong Wu, Yuling Zhao, Kelly Pate, Jonathan E. Frank, Nicole Massoud, Paul W. Stewart, Joel S. Perlmutter, Elena Batrakova
Summary: This study investigated the biodistribution and brain retention of PBMCs and EVs in adult rhesus macaques using PET/MRI imaging. The route of administration had a significant impact on brain retention of the carriers, with PBMCs showing higher brain retention when administered intrathecally. EVs demonstrated superior brain accumulation when administered intraperitoneally and intravenously, respectively. No cytotoxic effects were observed for either carrier in blood samples. Overall, living cells and EVs have great potential for drug delivery to the brain, and the route of administration plays a crucial role in CNS drug delivery.
Article
Chemistry, Multidisciplinary
Benjamin T. Ledford, Adam W. Akerman, Kui Sun, David C. Gillis, Jenna M. Weiss, Johnny Vang, Smaranda Willcox, Tristan D. Clemons, Hiroaki Sai, Ruomeng Qiu, Mark R. Karver, Jack D. Griffith, Nick D. Tsihlis, Samuel Stupp, John S. Ikonomidis, Melina R. Kibbe
Summary: This study reports the development of injectable supramolecular nanofibers that target fragmented elastin, matrix metalloproteinase 2, and membrane type 1 matrix metalloproteinase to reduce the risks associated with a ruptured abdominal aortic aneurysm. The results show that one of the nanofibers was able to better localize to the aneurysm tissue and had an optimal dose.
Article
Chemistry, Multidisciplinary
Limei Shen, Jingjing Li, Qi Liu, Manisit Das, Wantong Song, Xueqiong Zhang, Karthik Tiruthani, Oleksandra Dorosheva, Haiyang Hu, Samuel K. Lai, Rihe Liu, Leaf Huang
Summary: Interaction between different cell types in the tumor microenvironment affects tumor growth. Tumor-associated fibroblasts produce CXCL13, which recruits B cells to the tumor microenvironment. B cells in the tumor microenvironment differentiate into regulatory B cells (Bregs). CXCL13 also stimulates epithelial-mesenchymal transition (EMT) of tumor cells. Using plasmid DNA encoding a CXCL13 trap to reduce Bregs differentiation and normalize EMT suppresses tumor growth.
JOURNAL OF CONTROLLED RELEASE
(2022)
Article
Chemistry, Multidisciplinary
Anne M. Talkington, Morgan D. McSweeney, Timothy Wessler, Marielle K. Rath, Zibo Li, Tao Zhang, Hong Yuan, Jonathan E. Frank, M. Gregory Forest, Yanguang Cao, Samuel K. Lai
Summary: PEGylation is commonly used to prolong the circulation time of protein therapeutics and nanomedicines. However, individuals exposed to PEGylated therapeutics may develop antibodies specific to PEG, increasing the risk of hypersensitivity and accelerated drug clearance. In this study, a PBPK model was developed to investigate the impact of anti-PEG antibodies on the pharmacokinetics and biodistribution of PEGylated drugs.
JOURNAL OF CONTROLLED RELEASE
(2022)
Article
Medicine, Research & Experimental
Liu Zhou, Ruiling Long, Mei Hu, Nan Liu, Yue Feng, Lin Qiu, Zibo Li, Yue Chen, Li Wang
Summary: Boron neutron capture therapy (BNCT) is a promising cancer treatment strategy that utilizes boron-containing ligands. In this study, a series of substituted boramino acids were synthesized and evaluated for their potential use in BNCT with integrated positron emission tomography (PET). The compound R-[F-18]-5a demonstrated the best tumor uptake and stability among tested agents, making it a promising candidate for future evaluation in PET and BNCT combination therapy.
MOLECULAR PHARMACEUTICS
(2022)
Article
Biochemistry & Molecular Biology
Li Wang, Yubai Zhou, Xuedan Wu, Xinrui Ma, Bing Li, Ransheng Ding, Michael A. Stashko, Zhanhong Wu, Xiaodong Wang, Zibo Li
Summary: MerTK is abnormally expressed in various cancers, but the sensitivity of tumors to MerTK suppression may vary. In this study, a radiolabeled agent [F-18]-MerTK-6 was developed and showed prominent uptake in tumors in initial evaluation, suggesting it as a promising PET agent for MerTK imaging.
Article
Biotechnology & Applied Microbiology
Pritha Agarwalla, Edikan A. Ogunnaike, Sarah Ahn, Kristen A. Froehlich, Anton Jansson, Frances S. Ligler, Gianpietro Dotti, Yevgeny Brudno
Summary: This study introduces a novel implantable multifunctional scaffold (MASTER) that streamlines in vivo CAR-T cell manufacturing, resulting in the rapid generation and release of functional CAR-T cells in mice. MASTER shows improved therapeutic efficacy and persistence compared to conventional CAR-T cells, promising to transform CAR-T cell therapy.
NATURE BIOTECHNOLOGY
(2022)
Article
Multidisciplinary Sciences
Hongxia Li, Emily B. Harrison, Huizhong Li, Koichi Hirabayashi, Jing Chen, Qi-Xiang Li, Jared Gunn, Jared Weiss, Barbara Savoldo, Joel S. Parker, Chad Pecot, Gianpietro Dotti, Hongwei Du
Summary: Therapeutic options for non-small cell lung cancer patients with brain metastases are limited. CAR-T cells targeting B7-H3 and expressing the chemokine receptor CCR2b show improved accumulation in the brain and enhanced anti-tumor activity. This strategy could improve the efficacy of adoptive T-cell therapies in patients with solid tumors presenting with brain metastases.
NATURE COMMUNICATIONS
(2022)
Article
Cell Biology
Nazira El-Hage, Matthew J. Haney, Yuling Zhao, Myosotys Rodriguez, Zhanhong Wu, Mori Liu, Carson J. Swain, Hong Yuan, Elena V. Batrakova
Summary: We have developed a novel EV-based drug delivery system for the treatment of Batten disease (BD) by transporting the lysosomal enzyme TPP1. The EVs were loaded with TPP1 through transfection of parent cells and showed successful delivery to the brain in a mouse model of BD. The TPP1-loaded EVs exhibited therapeutic effects by eliminating lipofuscin aggregates, reducing inflammation, and improving neuronal survival, possibly through activation of the autophagy pathway. Continued research into effective therapies for BD is crucial for improving patient outcomes.
